# Delphine Dinard

> Delphine Dinard is a Series B investor at Ace Capital Partners backing Health Care. See 2 investments, check sizes, portfolio and contact details. Updated…

- Type: Angel Investor
- Fund: [Ace Capital Partners](https://shizune.co/investors/profile/ace-capital-partners)
- Location: Paris, France
- Total investments: 2
- Last investment: Jan 2018
- Lead investor: 50%
- Last updated: Sep 2026
- LinkedIn: https://www.linkedin.com/in/delphine-dinard-bb905823/

Delphine Dinard is a Series B investor at Ace Capital Partners in Paris focused on Health Care and Biotechnology. Delphine Dinard - Executive Director @ Ace Capital Partners

## Contacts

5 contacts available for Delphine Dinard: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/delphine-dinard?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 50% |
| Biotechnology | 1 | 50% |
| Medical Device | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Venture - Series Unknown | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Pherecydes Pharma | Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to itsouter membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria. | $10.7M | Series B | Jan 16, 2018 | http://pherecydes-pharma.com |
| Pherecydes Pharma | Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to itsouter membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria. | $2.7M | Venture - Series Unknown | Mar 18, 2015 | http://pherecydes-pharma.com |

2 of 2 investments shown.

## Co-investors
- [Auriga Partners](https://shizune.co/investors/profile/auriga-partners) — VC Fund, 2 deals together
- [FaDièse](https://shizune.co/investors/profile/fadise) — VC Fund, 1 deal together
- [Karista](https://shizune.co/investors/profile/karista) — VC Fund, 1 deal together
- [Omnes Capital](https://shizune.co/investors/profile/omnes-capital) — VC Fund, 1 deal together
- [GO CAPITAL](https://shizune.co/investors/profile/ouest-ventures) — VC Fund, 1 deal together

## About Ace Capital Partners

VC Fund · Paris, France

Ace invests with a sector-focused approach, active in Industrials and Technology. The firm builds partnerships with large corporates (including Airbus, Safran, Dassault Aviation, Thales, EDF, Naval Group, Sopra Steria), which invest in its funds and maintain an ongoing dialogue with the firm, enabling Ace to take a differentiated approach toinvesting. Ace provides capital for businesses going through transformation, with the ability to invest with a variety in growth, buyout, and restructuring situations. We focus on companies with a proven expertise in their market, and with high and resilient intrinsic value, but which require transformation to deliver on their potential. We act as a strategic partner to management as we transform operations, and restructure/grow the business both organically and through external growth. Ace is active throughout Europe and North America. The firm has offices in Paris, Toulouse, Bordeaux and Montreal, and accesses the global network of Tikehau Capital offices (London, Milan, Madrid, Brussels, New York, Singapore, Tokyo and Seoul). Investment strategies overview: - Growth Capital: investment in high/hyper growth companies raising money in Series A through C, active in the Cybersecurity and Digital Trust verticals o Investment amount: up to €50m o Sector of focus: Technology (e.g. Cybersecurity, Digital Trust) - Support Capital: development capital / special opportunities (minority or control) investments in companies requiring capital to stabilise and or grow operations o Investment amount: up to €50m o Sector of focus: Industrials (e.g. Aerospace, Defence) - Platform Capital: development capital / special opportunities (minority or control) investments in companies requiring capital to stabilise and or grow operations o Investment amount: €50-200m o Sector of focus: Industrials (e.g. Aerospace, Defence)

5 contacts available at Ace Capital Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Delphine Dinard | Executive Director | https://shizune.co/investors/profile/delphine-dinard |
| Quentin Besnard | Executive Director | https://shizune.co/investors/profile/quentin-besnard |
| Arnaud Coustillière | Operating Partner | https://shizune.co/investors/profile/arnaud-coustilli%C3%A8re |
| Eric Zanin | Operating Advisor | https://shizune.co/investors/profile/eric-zanin |
| Franck Crépin | Managing Director | https://shizune.co/investors/profile/franck-cr%C3%A9pin |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Delphine Dinard invest in?

Delphine Dinard invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series B and Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Delphine Dinard?

Public channels for Delphine Dinard include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Delphine Dinard last invest?

The most recent investment recorded for Delphine Dinard closed in Jan 2018. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co